Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Liminal BioSciences Inc. LMNL

Healthcare Biotechnology
Liminal BioSciences is a biopharmaceutical company focused on the discovery and development of novel, small molecule drug candidates for the treatment of patients suffering from fibrotic or inflammatory diseases that have a high unmet medical need. Liminal BioSciences operates on an integrated basis from our talent hubs in Laval, Quebec, Canada, and Cambridge, UK. Our common shares are listed for trading on the Nasdaq Global Market.


NDAQ:LMNL - Post by User

Liminal BioSciences Inc. > liminal is not prometic.
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(46)
•••
Comment by DryBoneson Apr 11, 2020 12:28am
92 Views
Post# 30898419

RE:RE:RE:RE:RE:re: liminal is not prometic.

RE:RE:RE:RE:RE:re: liminal is not prometic.working capital means very little.  It doesn't include long term assets or lang term debt.  The money in a biotech gets eaten very quickly.  Any biotech company with less that $250 miliion to fund research for even one drug is under funded and will have to go to the market.

Since LMNL has no track record or getting approvals, the likely hood of a new  pacement is high
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities